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Background: Reduced plasma nitrate (NOx) levels and increased urinary norepinephrine (U-NE) levels have been
described in severe obstructive sleep apnea (OSA), and are reverted by continuous positive airway pressure (CPAP).
The effect of CPAP on these biomarkers in mild-moderate OSA is not well understood.
The aim of this study was to compare NOx and U-NE levels and blood pressure (BP) between male patients with
mild-moderate and severe OSA and determine the impact of 1 month of CPAP therapy on these parameters.
Methods: We undertook a prospective study of 67 consecutive OSA patients (36 mild-moderate, 31 severe).
Measurements of plasma NOx at 11 pm, 4 am and 7 am, 24-h U-NE and ambulatory BP were obtained at baseline
and after 1 month of CPAP.
Results: At baseline, NOx levels showed a significant decrease during the night in both groups (p < 0.001). U-NE
level and BP were significantly higher in the severe OSA group. After 1 month of CPAP, there was a significant
increase in NOx levels and a reduction in U-NE level and BP only in patients with severe OSA.
Conclusions: One month of CPAP results in significant improvements in NOx levels, 24-h U-NE level and BP in
patients with severe OSA, but not in patients with mild-moderate OSA.
Trial registration: ClinicalTrials.gov: NCT01769807Background
Obstructive sleep apnea (OSA) is an increasingly recog-
nized health issue. Considerable evidence supports an in-
dependent association between OSA and cardiovascular
disease, which is particularly strong for systemic arterial
hypertension [1-3]. The pathogenesis of this association is
likely to be multifactorial, involving a diverse range of
mechanisms including increased sympathetic activity, sys-
temic inflammation, endothelial dysfunction, oxidative
stress and metabolic dysregulation [4,5].
Continuous positive airway pressure (CPAP) decreases
daytime somnolence and prevents cardiovascular compli-
cations in patients with severe OSA [6,7]. However, there
is no consensus on the cardiovascular benefits of CPAP
therapy in mild-moderate patients. The impact of mild* Correspondence: paulagpinto@gmail.com
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reproduction in any medium, provided the orforms of obstructive sleep apnea and their treatment on
cardiovascular outcomes remains controversial. The ob-
servational study by Buchner et al. [8] showed increased
cardiovascular morbidity in mild-moderate OSA patients
and demonstrated that OSA treatment improved cardio-
vascular outcome. They found that cardiovascular events
were more frequent in untreated mild-moderate OSA
patients, and that OSA treatment was associated with a
significant reduction (64%) in cardiovascular risk, inde-
pendent of age, gender and pre-existing cardiovascular
comorbidities.
Reduced circulating nitrate (NOx) levels, increased urin-
ary norepinephrine (U-NE) levels and increased blood
pressure (BP) have been described in patients with severe
OSA, and are reverted by CPAP [9-17]. The effect of
CPAP on these parameters has, however, not been studied
in mild-moderate OSA. Previous studies evaluating NOx
deficiency and sympathetic dysfunction have mainly fo-
cused on patients with severe OSA.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that sought to: 1) compare NOx and U-NE levels be-
tween male patients with mild-moderate and severe
OSA; 2) compare BP values between these patient
groups, and 3) determine whether CPAP therapy im-
proves NOx deficiency, sympathetic dysfunction and BP
in these patients.Methods
Study population
All patients were recruited from our institution’s sleep la-
boratory. OSA was diagnosed on the basis of symptoms
and a respiratory disturbance index (RDI) showing more
than 5 respiratory events/h on overnight polysomnography.
We recruited 67 consecutive male patients with OSA: 36
with mild-moderate OSA and 31 with severe OSA.
Patients were excluded if they met any of the following
criteria: 1) current smoker; 2) respiratory or cardiac dis-
ease (except for arterial hypertension); 3) renal, hepatic or
psychiatric disorder; 4) diabetes mellitus or dyslipidemia;
5) rhinitis, sinusitis or acute illness; 6) daytime hypoxemia
or hypercapnia; 7) therapy with oral nitrates, angiotensin-
converting enzyme inhibitors, beta-blockers, statins or
non-steroidal anti-inflammatory drugs; 8) presence of
central respiratory events on polysomnography; 9) previ-
ous CPAP therapy or uvulopalatopharyngoplasty. One pa-
tient from each group was also excluded because of
failure to comply with CPAP.
Patients were assessed for obstructive/restrictive lung
disease by a respiratory physician based on clinical evalu-
ation, pulmonary function testing, arterial blood gas meas-
urement and chest radiography, and for cardiac disease by
a cardiologist based on history, physical examination, elec-
trocardiography and echocardiography.
As recommended for the measurement of NOx levels,
all subjects were instructed to ingest a low nitrate/nitrite
diet [18]. They were also advised to avoid exercise on
urine collection days.
The study protocol was approved by Centro Hospitalar
Lisboa Norte’s Ethics Committee and all subjects gave
written informed consent. The study was performed in
accordance with the guidelines in the current revision of
the Declaration of Helsinki.
Study design
We performed a single-center, prospective study of OSA
patients. Data were collected in all subjects at baseline
and after 1 month of CPAP. These data included full
poly-somnography, ambulatory blood pressure monitor-
ing (ABPM), fasting venous blood collection at 11 pm,
4 am and 7 am for NOx levels and 24-h urine collection
for U-NE. Epworth sleepiness scale was administered
at all visits.Polysomnography
All subjects underwent full polysomnography (Embla
S7000, Embla, USA). Sleep stages were manually scored
according to the criteria of Rechtschaffen and Kales [19].
Respiratory events were classified according to the recent
scoring recommendations [20]. Apnea was defined as a
reduction of >90% in oronasal airflow lasting ≥10 seconds.
Hypopnea was defined as a decrease of >30% in oronasal
airflow lasting ≥10 seconds and associated with ≥4% de-
saturation from the pre-event baseline. Respiratory effort
related arousals were defined as a sequence of breaths
lasting at least 10 seconds characterized by flattening of
the nasal pressure waveform and leading to an arousal
from sleep. OSA was defined when RDI was ≥5 events/h
(mild-moderate was defined as RDI <30 and severe as
RDI ≥30).CPAP therapy
One week after the initial visit, an automated pressure
setting device (AutoSet Spirit, ResMed, Australia) was
given to all patients with predefined settings (minimal
pressure: 4 cmH2O; maximal pressure: 16 cmH2O) and
they were instructed to use this for 1 month. CPAP adap-
tation was performed by a sleep technician and patients
underwent an educational program for appropriate use of
the equipment. Patients were considered compliant with
CPAP if they used it for ≥4.5 h/night. Follow-up program
consisted of weekly phone calls and immediate correction
of adverse effects with optimization of CPAP settings, if
necessary.Ambulatory blood pressure monitoring
All patients underwent ABPM with a non-invasive port-
able validated recorder (Spacelab 90207, SpaceLabs Med-
ical, Redmond, WA, USA) at baseline and after 1 month
of CPAP. A BP cuff was fitted on the non-dominant arm
of the patient for 24 h. BP was recorded every 20 min dur-
ing the day and every 30 min during the night. A dipping
pattern was defined as a reduction in the average systolic
BP at night of >10% compared with daytime values. Based
on ABPM, hypertension was classified according to the re-
cent guidelines for the management of arterial hyperten-
sion [21]. For ethical reasons, anti-hypertensive treatment
was not withdrawn during the study.Blood sample collection and measurement of NOx
An intravenous catheter was inserted into an antecubital
vein and was kept patent by a continuous saline drip.
Plasma NOx levels were determined by the chemilu-
minescence technique, using a Sievers 280 NO Analyzer
(Sievers Instruments) as previously described [22-24].
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Sympathetic nervous system activity was estimated by
24-h U-NE levels using high-performance liquid chro-
matography as previously described [25,26].
Statistical analysis
Results are presented as mean ± SD or as percentages.
Comparisons between patients with mild-moderate and
severe OSA were performed using the non-paired t-test
or the Mann–Whitney U test when comparing mean
values between groups at baseline, and the paired t-test
when comparing mean values before and after CPAP
treatment. Multivariate ANOVA analysis was performed
to assess changes in plasma NOx levels during the night
and to compare these values before and after CPAP.
Subjects were stratified by BMI > 30 and BMI < 30 kg/
m2 to assess the effects of obesity on NOx and U-NE
levels. Association between categorical variables wasTable 1 Characteristics of the study population at baseline an
Mild/moderate OSA
Baseline
Age (yrs) 48 ± 10.4
Body mass index (Kg/m2) 29 ± 3.8*
Epworth score 11 ± 6.2#
RDI (n/h) 16 ± 6.8*
Mean SaO2 (%) 95 ± 1.3*
Minimum SaO2 (%) 86 ± 4.8*
SaO2 < 90% (% of TST) 1 ± 3.2*
ODI (n/h) 10 ± 9.5*
Arousal index (n/h) 23 ± 8.1*
Compliance (h/night) NA
95th percentile CPAP pressure (cmH2O) NA
24h MAP (mmHg) 91 ± 6.8*
Daytime BP (mmHg)
Systolic 127 ± 8.3*
Diastolic 81 ± 6.2*
Nighttime BP (mmHg)
Systolic 114 ± 7.9*
Diastolic 70 ± 7.6*
Nox 11pm (μm) 34.3 ± 21.8+
Nox 4am (μm) 29.4 ± 15.4+
Nox 7am (μm) 26.4 ± 14.1+
ΔNOX (%) 16.5 ± 18.5+
U-NE (μg/24h) 48.5 ± 19.9*
Values shown as mean ± SD. RDI, respiratory disturbance index; SaO2, arterial oxyge
arterial pressure; BP, blood pressure; NOX, nitrate levels; ΔNOX, percentage decrease
*: p < 0.05 comparison of baseline values between patients with severe and mild-m
#: p < 0.05 comparison between pre- and post-CPAP values (paired t-test).
+ p < 0.05 comparison between different time points and between pre- and post-CP
& p < 0.05 comparison between different time points and between pre- and post-CPevaluated by the chi-square test or the Fisher Exact test.
Bivariate relationships between variables were determined
by Pearson’s or Spearman’s correlation. A p value of <0.05
was considered statistically significant.
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS) version 17.0 for
Windows.Results
Table 1 shows characteristics of the study population at
baseline and after 1 month of CPAP. Sixty-seven con-
secutive OSA patients were studied: 36 patients with
mild-moderate OSA and 31 patients with severe OSA.
Patients with severe OSA had a significantly higher
body mass index (BMI) than patients with mild-moderate
OSA (p < 0.05). Also, those patients had more severe oxy-
gen desaturation than mild-moderate OSA (p < 0.05).d after 1 month of CPAP
patients (n = 36) Severe OSA patients (n = 31)
Post CPAP Baseline Post CPAP
NA 51 ± 6.3 NA
30 ± 3.8 35 ± 5.1* 35 ± 5.0
3.1 ± 2.5 12 ± 6.3 # 4.2 ± 3.2
# 3 ± 2.5 66 ± 24.2# 4 ± 2.3
# 96 ± 1.2 91 ± 4.8# 95 ± 1.2
# 93 ± 2.1 71 ± 9.9# 93 ± 2.2
# 0 ± 0.2 27 ± 26.6# 0 ± 0.1
# 0 ± 0.2 52 ± 20.5# 0 ± 0.2
# 16 ± 9.2 53 ± 18# 14 ± 7
6.3 ± 1.3 NA 6.6 ± 0.9
11.5 ± 1.8 NA 13.2 ± 1.5
92 ± 6.9 97 ± 8.1# 92 ± 9
127 ± 8.8 134 ± 10.9# 130 ± 10.1
70 ± 7.5 85 ± 5.8 # 80 ± 6.2
116 ± 10.3 125 ± 14.2# 119 ± 12.9
70 ± 7.5 76 ± 9.3# 73 ± 8.9
41.3 ± 22.2 34.5 ± 21.9 & 41.4 ± 19.8
37.7 ± 21.1 27.2 ± 14.4 & 37.4 ± 17.9
36.6 ± 19.5 24.3 ± 16.8 & 35.2 ± 16.7
9.3 ± 16.3 27.6 ± 20.1 & 0.79 ± 52.2
47 ± 21.3 73.9 ± 30.1# 55.4 ± 21.8
n saturation; TST, total sleep time; ODI, oxygen desaturation index; MAP, mean
in NOx during the night; U-NE, urinary norepinephrine; NA, Not applicable.
oderate OSA (unpaired t-test).
AP for patients with mild-moderate OSA (multivariate ANOVA analysis).
AP for patients with severe OSA (multivariate ANOVA analysis).
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At baseline, 61% of patients with severe OSA and 53% of
patients with mild-moderate OSA had excessive daytime
sleepiness with an Epworth sleepiness scale (ESS)
score >10 (p = 0.80). After CPAP, excessive daytime
sleepiness was completely reversed in all patients with
severe OSA and in 94% of patients with mild-moderate
OSA (2 mild-moderate patients still had an ESS
score >10 after CPAP; p = 0.13).
Patients with severe OSA had significantly higher BP
values than patients with mild-moderate OSA (Table 1).
Before CPAP, 83% of patients with severe OSA com-
pared with 69% of patients with mild-moderate OSA
had arterial hypertension (p = 0.93), however only 31%
of patients with severe OSA and 29% with mild-
moderate OSA were treated for hypertension. All treated
hypertensive patients with mild-moderate OSA had con-
trolled BP levels at baseline and 39% of them showed a
non-dipper nocturnal pressure pattern. In contrast, 55%
of patients with severe OSA showed a non-dipper pat-
tern (p > 0.05). The hypertensive medications were: cal-
cium antagonists, diuretics and angiotensin II receptor
antagonists.
Before CPAP, there were no differences in NOx levels
between patients with mild-moderate and severe OSA
for all times measured. NOx levels showed a significant
decrease during the night in both groups (p < 0.001)
(Table 1, Figure 1). The percentage of NOx reduction
during the night (ΔNOx) was significantly higher in pa-
tients with severe OSA than in patients with mild-
moderate OSA (27.6 ± 20.1% vs 16.5 ± 18.5%, p < 0.05).
24-h U-NE levels were significantly higher in patients
with severe OSA than in patients with mild-moderate
OSA (73.9 ± 30.1 vs 48.5 ± 19.91 μg/24h, p < 0.05)
(Table 1, Figure 2). There was a significant cor-
relation between U-NE levels and the sleep parameters
RDI (r = 0.63; p < 0.001), mean SaO2 (r = −0,47; p <
0.001), minimum SaO2 (r = −0.55; p < 0.001) and arousal
index (r = 0.59; p < 0.001).
The study population was also stratified by BMI > 30
and < 30 kg/m2 and there was no difference between
obese and non obese subjects in NOx and U-NE levels.Figure 1 NOx levels at different time points before and after 1 monthAfter CPAP
All patients who completed the study were CPAP com-
pliant. Compliance was similar in the mild-moderate
and severe groups (6.3 ± 1.3 vs 6.6 ± 0.9 h/night; p >
0.05). 95th percentile CPAP pressure was 11.5 ± 1.8 cm
H2O in patients with mild-moderate OSA and 13.2 ± 1.5
cm H2O in patients with severe OSA (p < 0.001). BMI
did not change significantly during the study period.
RDI and SaO2 indexes normalized in both patient
groups.
After CPAP, both groups had a rise in NOx, although
in patients with mild-moderate OSA rise in NOx did not
reach full statistical significance (p = 0.054; Figure 1,
Table 1). Comparison of the percentage in NOx level re-
duction during the night (ΔNOx) pre- and post-CPAP
showed a significant decrease only in patients with se-
vere OSA (27.6 ± 20.1% vs 0.79 ± 52.2%; p < 0.05).
Evaluation of sympathetic activity showed a significant
reduction in 24-h U-NE excretion after CPAP only in
patients with severe OSA (73.9 ± 30.1 to 55.4 ± 21.8 μg/
24 h; p < 0.05) (Table 1, Figure 2). Patients with severe
OSA had higher post-CPAP U-NE levels than patients
with mild-moderate OSA, however the difference was
not statistically significant.
After 1 month of CPAP, patients with severe OSA had a
significant decrease in 24-h MAP (p < 0.05), daytime sys-
tolic BP (p < 0.05) and diastolic BP (p < 0.05), and also
night-time systolic BP (p < 0.05) and diastolic BP (p < 0.05).
CPAP did not change BP in patients with mild-moderate
OSA. However, it is worth noting that final BP values of
patients with severe OSA were similar to BP levels of pa-
tients with mild-moderate OSA. Normal circadian dipper
pattern was not restored in non-dipper patients after
1 month of CPAP.
Discussion
Our study showed that there was a significant decrease
in plasma NOx levels during the night in patients with
both severe and mild-moderate OSA before CPAP, with
the percentage reduction being higher in patients with
severe OSA. After 1 month of CPAP, there was a signifi-
cant increase in NOx levels in patients with severe OSAof CPAP in patients with mild-moderate and severe OSA.
Figure 2 U-NE levels before and after 1 month of CPAP in patients with mild-moderate and severe OSA.
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moderate OSA. We demonstrated that patients with severe
OSA had higher baseline U-NE levels than patients with
mild-moderate OSA. After 1 month of CPAP, only patients
with severe OSA had significantly decreased U-NE levels
compared with pre-CPAP levels. We also found that 1
month of CPAP treatment reduced BP values only in pa-
tients with severe OSA.
The main strengths of our study were the experimen-
tal design (determination of NOx levels during the night)
and the comparison between two groups of patients with
different OSA severity.
NOx deficiency
Diet is a contributor to NOx levels [18] which has not
been addressed in previous studies [9,12]. In our study all
subjects were instructed to ingest a low nitrate/nitrite diet.
Previous studies have demonstrated that NOx produc-
tion is reduced in severe OSA [9,10,12]. We further eval-
uated different severity OSA patient groups through the
night. We demonstrated a significant decrease in NOx
levels during the night in patients with mild-moderate
and severe OSA, with a higher percentage reduction in
NOx levels in patients with severe OSA. Lavie et al. also
reported a decrease in NOx levels during the night in
eight patients with severe OSA [11].
There is some evidence that hypoxemia associated
with apnea could lead to decreased nitric oxide produc-
tion. As oxygen is a cosubstrate of nitric oxide (NO)
synthase (NOS), OSA related desaturations might result
in depressed synthesis of NO. Night-time hypoxia might
suppress the transcription of the endothelial NOS gene
and the stability of its mRNA, as suggested by cellculture experiments performed under hypoxic condi-
tions [27]. It has been demonstrated that NOS inhibitors
are increased in OSA and might contribute to lowered
NO levels [28].It is also possible that free oxygen radicals
generated by circulating neutrophils under conditions of
hypoxia-reoxygenation in untreated OSA might cause an
exaggerated destruction of NO [29]. These mechanisms
were not evaluated in the present study.
Previous studies have shown that in patients with se-
vere OSA, CPAP therapy to abolish sleep apnea results
in increased NOx levels, suggesting that whatever mech-
anism causes the suppression of NO synthesis or release
is acute and promptly reversible with the reversal of
sleep apnea [9-12]. Our study confirmed these results,
but did not show an increase in NOx levels in mild-
moderate patients. However, this finding could be re-
lated to low statistical power. Indeed, a higher sample
would probably reach statistical significance.
Sympathetic dysfunction
Previous studies have demonstrated high U-NE levels in
severe OSA patients [13-17]. Our findings showed signifi-
cantly higher 24-h U-NE levels in patients with severe
OSA compared with patients with mild-moderate OSA.
U-NE levels correlated with RDI, overnight oxygen desat-
uration and arousal index, suggesting that hypoxemia and
sleep fragmentation increased sympathetic activity.
It has also been shown that CPAP reduces U-NE levels
in patients with severe OSA [13,15,17]. Our study con-
firmed these results for patients with severe OSA and
demonstrated that there was no change in U-NE levels
following CPAP in patients with mild-moderate OSA.
The mechanisms explaining this observation are unclear,
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OSA, the overnight oxygen desaturation and the arousal
index related to respiratory events were not sufficient to
activate the sympathetic nervous system and thereby
modify U-NE levels. After 1 month of CPAP, U-NE
levels of patients with severe OSA were not significantly
different from those with mild-moderate OSA.Blood pressure
Previous studies have demonstrated that CPAP reduces BP
in patients with severe OSA [30-32]. This study also found
that both systolic and diastolic BP was reduced in daytime
and night-time measurements in patients with severe OSA.
In patients with mild-moderate OSA, no change in BP
values was found; however these patients already had their
BP controlled within the normal range at baseline. Alonso-
Fernández [12] also found that normotensive patients did
not change their BP values after CPAP.
The meta-analysis by Haentjens [33] showed that
greater CPAP related reductions in ambulatory BP were
observed in patients with more severe OSA and a better
nightly use of CPAP.
In our study, differences in the effects of CPAP on BP
between patients with mild-moderate OSA and patients
with severe OSA could not be explained by differences
in compliance rates, as compliance was similar between
groups. The high rate of CPAP compliance might be
explained by a very comprehensive follow-up program
with weekly phone calls and immediate correction of ad-
verse effects.
The non-reversal of the circadian BP pattern in our pa-
tients might be due to the short period of CPAP treat-
ment. In the study by Martinez Garcia [30], normalization
of the nocturnal BP pattern occurred after three months
of CPAP.
In this study, we found that 1 month of CPAP therapy
did not change NOx levels, 24-h U-NE levels or BP
values in patients with mild-moderate OSA. The absence
of response of one clinical parameter (BP) and two bio-
logical markers (NOx and U-NE) to CPAP therapy could
suggest that physiological effects of mild-moderate OSA
may not be disruptive enough to stimulate a rise in
U-NE and BP, as does severe OSA. It could also be that
a 1 month of CPAP was not enough to detect differences
between the groups. Also, CPAP might not have a pro-
tective cardiovascular effect in less severe forms of OSA.
Indeed, mortality follow-up of the Wisconsin Sleep
Cohort, including 20,963 subjects, indicated that only
patients with severe OSA had a significantly increased
cardiovascular mortality risk [34].
Limitations:
Some limitations should be addressed in our study,
namely a low sample population could compromisestatistical power. Also, our data are unable to generalize
to female, as we did not include women.
As apnea hypopnea index is more often referred in the
literature, using RDI could difficult the comparison be-
tween studies. Also, the maintenance of antihypertensive
therapy could have confounded results. The short time of
CPAP treatment is another possible limitation, as a longer
study period may have produced different results. In the
study by Martinez Garcia et al. [30], normalization of the
nocturnal BP pattern occurred after three months of
CPAP.
As our results may have implications for the CPAP
treatment of patients with mild-moderate OSA, it is im-
portant to undertake a larger controlled study with a
longer follow-up period.
Conclusions
Our study demonstrated that 1 month of CPAP treat-
ment significantly increases plasma NOx levels and re-
duces 24-h U-NE levels and BP in patients with severe
OSA, but did not demonstrate a significant change in
these values in patients with mild-moderate OSA.
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